Multiple Myeloma News
A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
Source: Myeloma : nature.com subject feeds Post Content Read More
Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
Source: Pharmacy Times articles The combination yields promising results but was associated with high incidence of toxicity and infection. Read More
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Source: Myeloma : nature.com subject feeds Post Content Read More
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
Source: Pharmacy Times articles For patients with multiple myeloma who may experience an infection while receiving teclistamab, supplementation with intravenous immunoglobulin (IVIG) can help resolve and prevent serious complications. Read More
Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Source: Myeloma : nature.com subject feeds Post Content Read More
Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
Source: Pharmacy Times articles The analysis shows patients achieved deep and durable responses despite being ineligible for the CARTITUDE-1 trial. Read More
Equecabtagene Autoleucel Shows Efficacy, Safety in Treatment of Patients With Heavily Pretreated Multiple Myeloma
Source: Pharmacy Times articles Patients with relapsed, refractory disease achieved deep, durable responses with equecabtagene autoleucel. Read More